

UC Irvine

Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health

Title

Erratum

Permalink

<https://escholarship.org/uc/item/0n30z6mf>

Journal

Western Journal of Emergency Medicine: Integrating Emergency Care with Population Health, 17(5)

ISSN

1936-900X

Author

Shwe, Samantha S

Publication Date

2016

DOI

10.5811/westjem.2016.8.32230

Copyright Information

Copyright 2016 by the author(s). This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

This Article Corrects: “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016”

Steve Christos, DO, MS*
Robin Naples, MD†

*Presence Resurrection Medical Center, Department of Emergency Medicine,
Chicago, Illinois

†Lewis Katz School of Medicine at Temple University, Department of Emergency
Medicine, Philadelphia, Pennsylvania

Electronically published August 23, 2016

Full text available through open access at http://escholarship.org/uc/uciem_westjem

DOI: 10.5811/westjem.2016.8.32230

[West J Emerg Med.669–670.]

West J Emerg Med. 2016 May;17(3):264-70.

Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016.

Christos S, Naples R.

Erratum in

West J Emerg Med. 2016 September;17(5):669-70. Dosage error in published figure; MEDLINE/PubMed Figure 3 is corrected and provided.

PMCID: PMC4899056 [PubMed - indexed for MEDLINE]

In the Review Article entitled “Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016,” published in the May 2016 issue of the *Western Journal of Emergency Medicine* (2016;17(3):264-70. DOI: 10.5811/westjem.2016.3.29294), there were the following errors in the published article.

Anticoagulant	Reversal/treatment options
Dabigatran	<p>Idarucizumab 5.0g IV total dose [DOSAGE ERROR CORRECTED] (given as two separate doses of 2.5g [DOSAGE ERROR CORRECTED] 15 minutes apart)</p> <p>Alternatives if idarucizumab is unavailable</p> <p>Hemodialysis</p> <p>Activated charcoal 100g po/NG if ingestion time <2 hours</p> <p>4F-aPCC (FEIBA)# 50 units/kg IV; <i>not to exceed 5000 units</i> (single dose only)</p> <p>Tranexamic acid 25mg/kg IV</p> <p>Desmopressin 0.3mcg/kg SQ or IV; limit to 2 IV doses given Increased risk of tachyphylaxis</p> <p>FFP: Not recommended rFVIIa: Not recommended</p>

Apixaban	<p>Activated charcoal 100g po/NG if ingestion time <6 hours</p> <p>4F-PCC (KCentra / Octaplex)^{#^} 50 units/kg IV; not to exceed 5000 units (single dose only)</p> <p>Tranexamic acid 25mg/kg IV</p> <p>Desmopressin 0.3mcg/kg SQ or IV; limit to 2 IV doses given Increased risk of tachyphylaxis</p> <p>Andexanet alpha[‡] 400mg IV bolus at 30mg/min followed by continuous infusion at 4mg/min [DOSAGE ERROR CORRECTED] for 120 minutes</p> <p>FFP: Not recommended rFVIIa: Not recommended</p>
Rivaroxaban	<p>Activated charcoal 100g po/NG; if ingestion time <8 hours</p> <p>4F-PCC (KCentra / Octaplex)^{#^} 50 units/kg IV; not to exceed 5000 units (single dose only)</p> <p>Tranexamic acid 25mg/kg IV</p> <p>Desmopressin 0.3mcg/kg SQ or IV; limit to 2 IV doses given Increased risk of tachyphylaxis</p> <p>Andexanet alpha[‡] 800mg IV bolus at 30mg/min followed by continuous infusion at 8mg/min [DOSAGE ERROR CORRECTED] for 120 minutes</p> <p>FFP: Not recommended rFVIIa: Not recommended</p>

Figure 3. Reversal of direct oral anticoagulants (DOACs) in patients with significant bleeding.

IV, intravenous; FFP, fresh frozen plasma; rFVIIa, Recombinant human Factor VIIa; PCC, prothrombin complex concentrates; FEIBA, Factor Eight Inhibitor Bypassing Activity; NG, nasogastric
#Off label use.

[^]4F-PCC contains heparin and is contraindicated in patients with a history of heparin induced thrombocytopenia.

[‡]Not currently available on market. FDA trials ongoing. Dosing based on published Phase 3 trial.